Laurel Wealth Advisors (North Carolina)’s AstraZeneca AZN Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-188	Closed	-$34.5K	–	233
2025 Q4	$34.5K	Buy	+188	New	+$33K	﹤0.01%	371
2025 Q2	–	Sell	-188	Closed	-$27.6K	–	232
2025 Q1	$27.6K	Hold	188	–	–	﹤0.01%	375
2024 Q4	$24.6K	Sell	188 -22	-10%	-$3.08K	﹤0.01%	394
2024 Q3	$32.7K	Buy	210 +22	+12%	+$3.55K	0.01%	351
2024 Q2	$29.2K	Hold	188	–	–	0.01%	340
2024 Q1	$25.4K	Hold	188	–	–	﹤0.01%	364
2023 Q4	$25.3K	Hold	188	–	–	﹤0.01%	343
2023 Q3	$25.4K	Hold	188	–	–	0.01%	342
2023 Q2	$26.8K	Sell	188 -187	-50%	-$27.5K	0.01%	339
2023 Q1	$52.1K	Buy	375 +187	+99%	+$25.2K	0.01%	276
2022 Q4	$25.4K	Hold	188	–	–	0.01%	314
2022 Q3	$21K	Hold	188	–	–	0.01%	327
2022 Q2	$25K	Hold	188	–	–	0.01%	317
2022 Q1	$25K	Hold	188	–	–	0.01%	322
2021 Q4	$22K	Hold	188	–	–	﹤0.01%	332
2021 Q3	$23K	Hold	188	–	–	0.01%	328
2021 Q2	$22K	Hold	188	–	–	﹤0.01%	367
2021 Q1	$19K	Hold	188	–	–	﹤0.01%	355
2020 Q4	$19K	Hold	188	–	–	﹤0.01%	352
2020 Q3	$21K	Hold	188	–	–	0.01%	307
2020 Q2	$20K	Buy	+188	New	+$19.4K	0.01%	310

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Laurel Wealth Advisors (North Carolina)'s AZN Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 188 shares — an estimated $34.5K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in AZN in Q2 2020 and held it in 21 quarters. The position peaked at $52.1K in Q1 2023. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Laurel Wealth Advisors (North Carolina) reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 188 AstraZeneca shares in Q1 2026, an estimated $34.5K.
Laurel Wealth Advisors (North Carolina) first reported a position in AstraZeneca in Q2 2020 and held it in 21 quarters.
Laurel Wealth Advisors (North Carolina)'s AstraZeneca position peaked at $52.1K in Q1 2023.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.